Brokers Offer Predictions for REGENXBIO FY2026 Earnings

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2026 earnings per share (EPS) estimates for shares of REGENXBIO in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of $0.28 per share for the year, up from their previous forecast of ($0.52). The consensus estimate for REGENXBIO's current full-year earnings is ($4.85) per share. Leerink Partnrs also issued estimates for REGENXBIO's FY2027 earnings at ($0.14) EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.21 EPS.

A number of other research firms also recently weighed in on RGNX. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price target on shares of REGENXBIO in a research note on Wednesday, January 15th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. StockNews.com downgraded REGENXBIO from a "hold" rating to a "sell" rating in a research report on Thursday, January 23rd. Morgan Stanley restated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Finally, Raymond James reiterated an "outperform" rating and set a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, REGENXBIO currently has a consensus rating of "Moderate Buy" and an average target price of $34.82.

REGENXBIO Stock Performance

Shares of RGNX remained flat at $8.43 during mid-day trading on Monday. 624,320 shares of the company traded hands, compared to its average volume of 1,076,326. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The business has a fifty day moving average of $8.11 and a 200-day moving average of $10.10. The company has a market cap of $417.66 million, a PE ratio of -1.68 and a beta of 1.29.

Institutional Investors Weigh In On REGENXBIO

A number of large investors have recently added to or reduced their stakes in the company. Redmile Group LLC increased its position in shares of REGENXBIO by 7.1% during the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company's stock worth $51,327,000 after acquiring an additional 323,100 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares during the last quarter. Millennium Management LLC grew its stake in REGENXBIO by 84.8% during the 2nd quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company's stock valued at $3,586,000 after purchasing an additional 140,666 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in REGENXBIO during the 4th quarter worth approximately $1,062,000. Finally, Raymond James Financial Inc. acquired a new position in shares of REGENXBIO in the 4th quarter valued at approximately $568,000. 88.08% of the stock is owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.